Cargando…

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are impacting the management of dyslipidemia to the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hongzhen, Chen, Xiaomin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185746/ https://www.ncbi.nlm.nih.gov/pubmed/37200976 http://dx.doi.org/10.3389/fcvm.2023.1138787

Ejemplares similares

Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial
por: Xia, Jiachun, et al.
Publicado: (2022)

Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome
por: Mensink, F. B., et al.
Publicado: (2022)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

Effects of PCSK9 inhibitors on coronary microcirculation, inflammation and cardiac function in patients with CHD after PCI: a protocol for systematic review and meta-analysis
por: Ye, Xuejiao, et al.
Publicado: (2023)

PCSK9 inhibitors in a renal transplant patient complicated with hepatitis B: A case report and literature review
por: Lv, Pinchao, et al.
Publicado: (2022)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

PCSK9 Gene E670G Polymorphism and Coronary Artery Disease: An Updated Meta-Analysis of 5,484 Subjects
por: Li, Yan-yan, et al.
Publicado: (2020)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
por: Banach, Maciej, et al.
Publicado: (2023)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
por: Wong, Nathan D., et al.
Publicado: (2019)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE(−/−) Mice
por: Jin, Ping, et al.
Publicado: (2021)

PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy
por: Hajar, Rachel
Publicado: (2019)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

SUN-574 A1AT: Novel Inhibitor of Active PCSK9
por: Melendez, Quantil, et al.
Publicado: (2020)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Neoatherosclerosis in Sirolimus-Eluting Stents After Paclitaxel-Coated Ballooning Cannot Be Stabilized Despite PCSK9 Inhibitor Therapy
por: Miyoshi, Toru, et al.
Publicado: (2019)

Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
por: Macchi, Chiara, et al.
Publicado: (2022)

FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)

SAT-576 Possible Involvement of Thyroid Function in PCSK9 Inhibitor Therapy
por: Iwabuchi, Masayasu
Publicado: (2020)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
por: Metkus, Thomas S., et al.
Publicado: (2022)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
por: van Solingen, Coen, et al.
Publicado: (2021)

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
por: Cao, Ye-Xuan, et al.
Publicado: (2018)

Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art
por: Iannuzzo, Gabriella, et al.
Publicado: (2021)

Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State
por: Louloudis, Georgios, et al.
Publicado: (2021)

Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale
por: Kostapanos, Michael S., et al.
Publicado: (2019)

Editorial: Multimodality Imaging in Acute Coronary Syndrome
por: Wang, Yining, et al.
Publicado: (2022)

Corrigendum: Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State
por: Louloudis, Georgios, et al.
Publicado: (2022)

Gallstone disease and the risk of cardiac mortality in patients with acute coronary syndrome
por: Su, Wen, et al.
Publicado: (2022)

Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
por: Huang, Sheng-Wei, et al.
Publicado: (2022)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4jhk632e29e07bahsg9jm8r1qg